Anebulo Pharmaceuticals Inc
anebulo.comAnebulo Pharmaceuticals Inc (NASDAQ: ANEB) is a clinical-stage pharmaceutical company developing small-molecule drug candidates. The company has no approved products and generates no product revenue, funding operations through equity offerings and debt financing, including a Loan and Security Agreement dated November 13, 2023, and an Amended and Restated Loan Agreement dated February 10, 2025. Anebulo qualifies as an emerging growth company and a smaller reporting company under SEC rules as of the 10-K filed September 29, 2025. Expenses consist of direct third-party costs under agreements with contract research organizations (CROs) and contract manufacturing organizations (CMOs), along with internal research and development costs. The company relies entirely on third-party manufacturers and contract partners for drug development and manufacturing. CEO Richard Anthony Cunningham joined under an employment agreement dated October 5, 2023. EisnerAmper LLP has served as the company's auditor since 2020.
Products & Services
Clinical-stage small-molecule drug candidates. No approved products as of the filing date. Development activities rely on CRO and CMO partnerships. The filing references potential regulatory exclusivity pathways including new chemical entity (NCE) five-year exclusivity and orphan drug designation upon any future FDA approval.
Revenue Model
No product revenue as of the 10-K filed September 29, 2025. Operations are funded through equity issuances, including a Securities Purchase Agreement dated December 23, 2024, and secured debt facilities. The company is pre-commercial.
Customers & Markets
No commercial customers as of the 10-K filed September 29, 2025. Target end market is the pharmaceutical/therapeutic drug market, contingent on future FDA approval of product candidates.
Geographic Exposure
United States-based operations. No geographic revenue breakdown disclosed, as the company has no product revenue.
Financial Snapshot
Loading...
